Physician

Internal Medicine

Philip T. Leese, MD is an expert in the field of Internal Medicine. He attended Creighton University School of Medicine. Creighton University School of Medicine has a rank of 79 in research and a 78 in primary care Philip Leese is a published doctor and has 38 publications published. The lastest was: 'Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function.'

Publications

---

• Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam.
• The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate.
• QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
• A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004.
• Safety and pharmacokinetic evaluation of intravenous vaccinia immune globulin in healthy volunteers.
• A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women.
• The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial.
• Valdecoxib does not impair platelet function.
• The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers.
• Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise.
• Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches.
• The effect of a single dose of osteoprotegerin in postmenopausal women.
• Randomized safety studies of intravenous perflubron emulsion. II. Effects on immune function in healthy volunteers.
• Randomized safety studies of intravenous perflubron emulsion. I. Effects on coagulation function in healthy volunteers.
• Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial.
• Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone.
• Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function.
• The pharmacokinetic-pharmacodynamic (Digit Symbol Substitution Test) relationship of flumazenil in a midazolam steady-state model in healthy volunteers.
• Human pharmacologic trials with iohexol.
• Bioavailability and pharmacokinetics of a new sustained-release potassium chloride tablet.
• The development of specific IgG4 after immunotherapy with standardized extracts.
• Pharmacokinetics of leucovorin calcium after intravenous, intramuscular, and oral administration.
• Ferrioxamine as a magnetic resonance contrast agent. Preclinical studies and phase I and II human clinical trials.
• Effect of cetamolol on epinephrine-induced hypokalemia.
• Etintidine-theophylline interaction study in humans.
• Pharmacokinetic and pharmacodynamic comparison of an osmotic release oral metoprolol tablet and the metoprolol conventional tablet.
• Safety and tolerability of single intravenous doses of T cell modulatory peptide (TCMP-80) in healthy volunteers.
• Hepatobiliary MR imaging: first human experience with MnDPDP.
• A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent.
• Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis.
• Efficacy and safety of cetirizine therapy in perennial allergic rhinitis.
• Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate.
• Concomitant administration of lumiracoxib and a triphasic oral contraceptive does not affect contraceptive activity or pharmacokinetic profile.
• Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study.
• Population PK-PD model for Fc-osteoprotegerin in healthy postmenopausal women.
• Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589.
• Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device.

Schools

---

• Creighton Univ Sch Of Med

Doctors Specialties

---

• Internal Medicine

Accepted Insurances

---

Education

---

• Creighton University
• Creighton University School of Medicine

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Lawrence D. Riffel, MD This Doctor is OpenDoctor Recommended.
	Dr. Carrie W. Lehr, MD This Doctor is OpenDoctor Recommended.
	Dr. Stephanie F. Snyder, MD This Doctor is OpenDoctor Recommended.
	Dr. Kenneth R. Kopp, MD This Doctor is OpenDoctor Recommended.
	Dr. Haroon C. Khalid, MD
	Dr. John A. Mallory, MD This Doctor is OpenDoctor Recommended.
	Dr. Benjamin Petelin, DO This Doctor is OpenDoctor Recommended.
	Dr. Sheena R. Spielberg, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael Monaco, MD This Doctor is OpenDoctor Recommended.
	Dr. Douglas J. McKee, MD
	Dr. Michelle R. Lester, MD This Doctor is OpenDoctor Recommended.
	Dr. Devon J. Weprich, DO This Doctor is OpenDoctor Recommended.
	Dr. David B. Parmet, MD This Doctor is OpenDoctor Recommended.
	Dr. Daniel P. Gaughan, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog